This is a preview and has not been published.

APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells

Authors

  • Ali Haider Alhammer Department of Medical and Molecular Biotechnology, Biotechnology Research Center, Al-Nahrain University, Baghdad, Iraq. https://orcid.org/0000-0002-1116-7987
  • Shaymaa Ismael Al-juboori Department of Biology, College of Science for Women, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0002-5925-8722
  • Shahad Ali Mudhafar Department of Medical and Molecular Biotechnology, Biotechnology Research Center, Al-Nahrain University, Baghdad, Iraq.

DOI:

https://doi.org/10.21123/bsj.2024.10135

Keywords:

APR-246, Combination, Doxorubicin, Pancreatic Cancer, p53 reactivator

Abstract

Pancreatic cancer (PC) is a disease with a high mortality rate, and the early diagnosis of PC is still challenging. The 5-year relative survival rate remains below 8%, and therapeutic strategies are ineffective at increasing patient survival rates. In PC cells, resistance to treatment has been associated with genetic changes that initiate aberrant developmental signaling pathways; therefore, new strategies for treating PC are warranted. Here, we sought to explore the small molecule p53 reactivator, APR-246, either as a mono-drug or combined with doxorubicin (Doxo) in the p53 mutant (p53-mut) AsPC-1 PC cell line. Cytotoxicity of APR-246 and Doxo was studied alone or in combination with the AsPC-1 cell line with MTT assay. CalcuSyn software was used to calculate the combination index (CI), which was based on the Chou and Talalay technique. Apoptosis was assessed after staining with Acridine orange/ethidium bromide (AO/EB). Morphological alterations were examined under a 200x magnification by an inverted microscope. Gene expression was quantified using quantitative reverse transcription PCR assay (RT-qPCR). APR-246 alone exhibited modest anti-proliferative effects, while Doxo combined with APR-246 showed synergistic effects associated with morphological change; no more enhanced apoptosis was observed, as supported by NOXA gene levels. In conclusion, APR-246, whether monotherapy or combined with Doxo, was hindering the proliferation of p53-mut AsPC-1 PC cells, and further in vitro and in vivo research is warranted.

Downloads

Download data is not yet available.

References

Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019; 10(1): 10. https://doi.org/10.14740/wjon1166

Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37: 1-13.https://doi.org/10.1186/s13046-018-0705-7

Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020; 13(1): 1-20.https://doi.org/10.1186/s13045-020-00958-3

Du J, Gong H, Xiao H. Somatic TP53 mutations and comparison of different TP53 functional domains in human cancers: Data analysis from the IARC TP53 database and the National Cancer Institute GDC data portal. Med Data Min. 2021; 4(3): 1-10.https://doi.org/10.12032/MDM2021033003

Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022; 29(5): 946-60.https://doi.org/10.1038/s41418-022-00988-z

Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review. Molecules (Basel, Switzerland). 2022; 27(14): 4478.https://doi.org/10.3390/molecules27144478

Mohammed I, Alhammer AH, Arif IS. The p53 reactivator PRIMA-1(MET) synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells. Invest New Drugs. 2023; 41(4): 587-95.https://doi.org/10.1007/s10637-023-01380-5

Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021; 39(14): 1584-94.https://doi.org/10.1200/jco.20.02341

Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F, et al. Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still A Mutant P53-Dependent Affair?. Cells. 2021; 10(1): 98.https://doi.org/10.3390/cells10010098

Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023; 10(4): e272-e83.https://doi.org/10.1016/S2352-3026(22)00403-3

Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investig New Drugs. 2014; 32: 783-94.https://doi.org/10.1007/s10637-014-0090-9.

Ali SM, Al-Karam LQ, Alhammer AJN. In Vitro Cancer Cells Therapy with Nano-gold Depending on its Optical Properties. Neuroquantology 2022; 20(2): 57.https://doi.org/10.14704/nq.2022.20.2.NQ22025

Alfardan RJBSJ. Small Nuclear RNA 64 (snoRNA64): A novel Tumor Biomarker for Pancreatic Cancer. Baghdad Sci J. 2023; 20((5Suppl.)): 1873-81.https://doi.org/10.21123/bsj.2023.7135

Nashaan FA, Al-Rawi MS, Alhammer AH, Rabie AM, Tomma JH. Synthesis, characterization, and cytotoxic activity of some imides from galloyl hydrazide. Eurasian Chem Commun. 2022; 4(10): 966-75.https://doi.org/10.22034/ecc.2022.340135.1453

Al-Juboori SKE, Al-Juboori SIK. Hepatocellular Carcinoma Prediction and early Diagnosis of Hepatitis B and C viral infection using miR-122 and miR-223 in a sample of Iraqi patients. Baghdad Sci J. 2023; 20(4(SI)): 1520.https://doi.org/10.21123/bsj.2023.9065

Ploner C, Kofler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene. 2008; 27 Suppl 1(Suppl 1): S84-92.https://doi.org/10.1038/onc.2009.46

Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1): 31-46.https://doi.org/10.1158/2159-8290.cd-21-1059

Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg. 2021; 25(3): 315-27.https://doi.org/10.14701/ahbps.2021.25.3.315

Guo Y, Tang Y, Lu G, Gu J. p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act. Nutrients. 2023; 15(10): 2259-82.https://doi.org/10.3390/nu15102259

Bykov VJ, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018; 18(2): 89-102.https://doi.org/10.1038/nrc.2017.109.

Yoshikawa N, Kajiyama H, Nakamura K, Utsumi F, Niimi K, Mitsui H, et al. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells. Oncol Rep. 2016; 35(5): 2543-52.https://doi.org/10.3892/or.2016.4653

Liu J, Huang Y, Liu Y, Chen Y. Irisin enhances doxorubicin-induced cell apoptosis in pancreatic cancer by inhibiting the PI3K/AKT/NF-κB pathway. Med Sci Monit. 2019; 25: 6085.https://doi.org/10.12659/MSM.917625

Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and NoxaAntimyeloma Activity of PRIMA-1Met. Mol Cancer Ther. 2013; 12(11): 2331-41.https://doi.org/10.1158/1535-7163.MCT-12-1166.

Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015; 6(6): e1794.https://doi.org/10.1038/cddis.2015.143

Müller M, Rösch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, et al. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers. 2021; 13(17): 4476-99.https://doi.org/10.3390/cancers13174476

Basu B, Gourley C, Gabra H, Vergote IB, Brenton JD, Abrahmsen L, et al. PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC). Ann Oncol. 2016; 27: vi123.https://doi.org/10.1093/annonc/mdw368.29

Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016; 6: 21.https://doi.org/10.3389/fonc.2016.00021.

Basile KJ, Aplin AE. Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res. 2012; 2(6): 726-35

Lu T, Zou Y, Xu G, Potter JA, Taylor GL, Duan Q, et al. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK. Oncotarget. 2016; 7(50): 83017.https://doi.org/10.18632/oncotarget.12940

Yang MC, Lin RW, Huang SB, Huang SY, Chen WJ, Wang S, et al. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. Cell Cycle. 2016; 15(3): 394-402.https://doi.org/10.1080/15384101.2015.1127470

Almohaidi AMS, Hassan FM, Rothan H. Editorial: Current advances in anti-infective strategies. Baghdad Sci. J. 2023;20(5):1570. https://doi.org/10.21123/bsj.2023.9731

Downloads

Issue

Section

article